Gatipotuzumab
Gatipotuzumab
Gatipotuzumab (pronunciation: ga-ti-po-tu-zu-mab) is a monoclonal antibody designed for the treatment of various types of cancer. It is a type of immunotherapy that targets and binds to the MUC1 protein, which is overexpressed in many types of cancer.
Etymology
The name "Gatipotuzumab" follows the World Health Organization's guidelines for the nomenclature of monoclonal antibodies. The suffix "-mab" indicates that it is a monoclonal antibody, while the infix "-tuzu-" suggests that it targets tumors.
Mechanism of Action
Gatipotuzumab works by binding to the MUC1 protein on the surface of cancer cells. This binding triggers an immune response that leads to the destruction of the cancer cells. The MUC1 protein is overexpressed in many types of cancer, making Gatipotuzumab a potential treatment for a wide range of cancers.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Immunotherapy: A type of cancer treatment that helps your immune system fight cancer.
- MUC1: A protein that is overexpressed in many types of cancer.
See Also
External links
- Medical encyclopedia article on Gatipotuzumab
- Wikipedia's article - Gatipotuzumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski